Syros Pharmaceuticals (SYRS) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS
Syros Pharmaceuticals (NASDAQ:SYRS) issued its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07, Bloomberg Earnings reports. The company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.33 million.
Shares of Syros Pharmaceuticals traded down $0.24, hitting $11.33, during trading on Wednesday, Marketbeat reports. 1,402 shares of the company’s stock traded hands, compared to its average volume of 113,840. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.35. The stock has a market capitalization of $331.32 million, a PE ratio of -5.43 and a beta of -2.44.
Several equities analysts have recently weighed in on SYRS shares. BidaskClub downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 24th. Cann restated a “buy” rating and set a $28.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, May 10th. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $20.88.
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Article: Market Capitalization
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.